Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
C10 AX09
|
| gptkbp:bioavailability |
approximately 93%
|
| gptkbp:brand |
gptkb:Zetia
|
| gptkbp:can_be_combined_with |
gptkb:simvastatin
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
liver disease
pregnancy breastfeeding |
| gptkbp:dosage_form |
10 mg
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zetia
|
| gptkbp:ingredients |
gptkb:ezetimibe
|
| gptkbp:interacts_with |
antacids
statins fibrates |
| gptkbp:invention |
gptkb:2020
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
gptkb:2002
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache muscle pain abdominal pain diarrhea |
| gptkbp:structure |
C24 H21 F2 N3 O3 S
|
| gptkbp:used_for |
lowering cholesterol
|
| gptkbp:bfsParent |
gptkb:Merck_Sharp_&_Dohme_Corp.
gptkb:Merck_&_Co.,_Inc. |
| gptkbp:bfsLayer |
6
|